Citius Pharmaceuticals, Inc. reported $7.1 million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR and has $17 million in cash and cash equivalents as of June 30, 2026.

US · 2026-08-14

1. Step 1 · The triggerCitius Pharmaceuticals reports $7.1m in revenue from LYMPHIR sales.
2. Step 2 · Knock-onIncreased revenue enhances investor confidence and potential for future funding.
3. Step 3 · Reaches youPositive market perception may lead to higher stock valuation and investment interest.

The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.

Source: PR Newswire

This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.